SECURITIES AND EXCHANGE COMMISSION
                                      
                           WASHINGTON, D.C.  20549
                                      
                                  FORM 8-K


                               CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                       SECURITIES EXCHANGE ACT OF 1934
                      Date of Report:  January 14, 1998
                                      


                               MEDIMMUNE, INC.
           (Exact name of registrant as specified in its charter)



                      Commission File Number:  0-19131
                                      
                                      
                                      
                                      
          Delaware                                    52-1555759
     (State of Incorporation)                     (I.R.S. Employer
                                                  Identification No.)



     35 West Watkins Mill Road, Gaithersburg, MD      20878
     (Address of principal executive offices)       (Zip Code)


          Registrant's telephone number, including area code (301) 417-0770


                No Exhibits are being filed with this report
                                      
                                      
CytoGam and RespiGam are registered trademarks of the Company.


                               MEDIMMUNE, INC.
                         Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated January 13, 1998:

             MEDIMMUNE ANNOUNCES $66.3 MILLION PRIVATE PLACEMENT
                                      
Gaithersburg, MD, January 13, 1998 -- MedImmune, Inc. (Nasdaq:MEDI) today
announced that 1,700,000 new shares of common stock will be issued at $39 per
share to a group of three institutional investors including BB Biotech,
Investor AB and Invesco Funds Group. The private placement was self-managed
by MedImmune. The closing of the transaction is conditioned upon the
effectiveness of a registration statement to be filed with the U.S.
Securities and Exchange Commission covering resale by purchasers.

The Company intends to use the net proceeds to finance the potential market
introduction of SynagisT (palivizumab, formerly known as MEDI-493), if and
when approved by the U.S. Food and Drug Administration, and for working
capital and general corporate purposes.  Upon closing of the financing,
MedImmune will have 26.2 million shares outstanding.

SynagisT is a humanized monoclonal antibody being developed by MedImmune for
prevention of serious respiratory syncytial virus (RSV) disease in infants
and young children. RSV is the most common cause of lower respiratory
infections in infants and children worldwide.

MedImmune, Inc. is a biotechnology company focused on developing and
marketing products for the prevention and treatment of infectious diseases
and for use in transplantation medicine. MedImmune currently markets two
products through its hospital-based sales force and has five new product
candidates in clinical trials. MedImmune is located in Gaithersburg, MD.

This announcement may contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties.  Such
statements reflect management's current views and are based on certain
assumptions.  Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the Company's filings with the U.S. Securities and
Exchange Commission.  MedImmune cautions that there can be no assurance that
SynagisT will be licensed for marketing by regulatory authorities.


(REGISTRANT)      MEDIMMUNE, INC.




BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, President and Chief Operating Officer
                                (Principal financial and accounting officer)
(DATE)            January 14, 1998
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 4068}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19131", "film-number": "98506827"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION
                                      
                           WASHINGTON, D.C.  20549
                                      
                                  FORM 8-K

                               CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                       SECURITIES EXCHANGE ACT OF 1934
                      Date of Report:  January 14, 1998
                                      

                               MEDIMMUNE, INC.
           (Exact name of registrant as specified in its charter)

                      Commission File Number:  0-19131
                                      
                                      
                                      
                                      
          Delaware                                    52-1555759
     (State of Incorporation)                     (I.R.S. Employer
                                                  Identification No.)

     35 West Watkins Mill Road, Gaithersburg, MD      20878
     (Address of principal executive offices)       (Zip Code)

          Registrant's telephone number, including area code (301) 417-0770

                No Exhibits are being filed with this report
                                      
                                      
CytoGam and RespiGam are registered trademarks of the Company.

                               MEDIMMUNE, INC.
                         Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated January 13, 1998:

             MEDIMMUNE ANNOUNCES $66.3 MILLION PRIVATE PLACEMENT
                                      
Gaithersburg, MD, January 13, 1998 -- MedImmune, Inc. (Nasdaq:MEDI) today
announced that 1,700,000 new shares of common stock will be issued at $39 per
share to a group of three institutional investors including BB Biotech,
Investor AB and Invesco Funds Group. The private placement was self-managed
by MedImmune. The closing of the transaction is conditioned upon the
effectiveness of a registration statement to be filed with the U.S.
Securities and Exchange Commission covering resale by purchasers.

The Company intends to use the net proceeds to finance the potential market
introduction of SynagisT (palivizumab, formerly known as MEDI-493), if and
when approved by the U.S. Food and Drug Administration, and for working
capital and general corporate purposes.  Upon closing of the financing,
MedImmune will have 26.2 million shares outstanding.

SynagisT is a humanized monoclonal antibody being developed by MedImmune for
prevention of serious respiratory syncytial virus (RSV) disease in infants
and young children. RSV is the most common cause of lower respiratory
infections in infants and children worldwide.

MedImmune, Inc. is a biotechnology company focused on developing and
marketing products for the prevention and treatment of infectious diseases
and for use in transplantation medicine. MedImmune currently markets two
products through its hospital-based sales force and has five new product
candidates in clinical trials. MedImmune is located in Gaithersburg, MD.

This announcement may contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties.  Such
statements reflect management's current views and are based on certain
assumptions.  Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the Company's filings with the U.S. Securities and
Exchange Commission.  MedImmune cautions that there can be no assurance that
SynagisT will be licensed for marketing by regulatory authorities.

(REGISTRANT)      MEDIMMUNE, INC.

BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, President and Chief Operating Officer
                                (Principal financial and accounting officer)
(DATE)            January 14, 1998